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ABSTRACT: The ACTN3 R577X (rs1815739) genotype
has been associated with athletic status and muscle
phenotypes, although not consistently. Our objective was
to conduct a meta-analysis of the published literature on
athletic status and investigate its associations with
physical capability in several new population-based
studies. Relevant data were extracted from studies in
the literature, comparing genotype frequencies between
controls and sprint/power and endurance athletes. For
life course physical capability, data were used from two
studies of adolescents and seven studies in the Healthy
Ageing across the Life Course (HALCyon) collaborative
research program, involving individuals aged between 53
and 901 years. We found evidence from the published
literature to support the hypothesis that in Europeans the
RR genotype is more common among sprint/power
athletes compared with their controls. There is currently
no evidence that the X allele is advantageous to
endurance athleticism. We found no association between
R577X and grip strength (P5 0.09, n5 7,672 in males;
P5 0.90, n5 7,839 in females), standing balance, timed
get up and go, or chair rises in our studies of physical
capability. The ACTN3 R577X genotype is associated
with sprint/power athletic status in Europeans, but does
not appear to be associated with objective measures of
physical capability in the general population.
Hum Mutat 32:1008–1018, 2011. & 2011
Wiley-Liss, Inc.
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Introduction
Genetic association studies have identified several loci asso-
ciated with physical performance phenotypes [Bray et al., 2009].
One of the more common investigations has been into a single
nucleotide polymorphism (SNP) in the alpha-actinin-3 (ACTN3;
MIM] 102574) gene. ACTN3 is expressed in fast twitch muscle
fibers [North et al., 1999], the fiber types that contract quickly but
are less resistant to fatigue [Allen et al., 2008]. SNP rs1815739
(R577X) encodes a premature stop codon leaving individuals with
two copies of the T allele (XX homozygotes) completely deficient
in the protein [North et al., 1999]. There is, however, no evidence
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for associations with disease phenotypes [North et al., 1999; Rubio
et al., 2007]. However, studies investigating R577X genotype
frequencies in athletes and the general population have found that
its C (R) allele is overrepresented in sprinters or power athletes
compared with controls [Eynon et al., 2009b; Papadimitriou
et al., 2008; Yang et al., 2003] or endurance athletes [Eynon et al.,
2009b; Niemi and Majamaa, 2005; Yang et al., 2003]. Other
reports show its overrepresentation in professional soccer
players [Santiago et al., 2008], artistic gymnasts [Massidda et al.,
2009], endurance [Ahmetov et al., 2008], strength- and power-
oriented athletes [Druzhevskaya et al., 2008; Roth et al., 2008]
compared with the general population. In addition, the ACTN3
R577X genotype may also influence sprint performance in
combination with other genotypes [Eynon et al., 2009a, 2010].
However, many studies have not found differences in the R577X
genotype frequencies between endurance athletes and controls
[Doring et al., 2010; Muniesa et al., 2008; Paparini et al., 2007;
Saunders et al., 2007; Yang et al., 2007] or between sprint/power
athletes and controls [Scott et al., 2010; Yang et al., 2007], and no
summary meta-analysis has been presented.
Genotypes associated with athletic status may also contribute to
the interindividual variability in physical capability, the capacity
to undertake the physical tasks of daily living, through effects on
muscle function or maintenance. Physical capability declines from
midlife onward [Himann et al., 1988; Mathiowetz et al., 1985] and
within specific age groups lower levels of physical capability, as
assessed by objective measures including grip strength and
standing balance, have been associated with poorer cognition
[Coppin et al., 2006; Deary et al., 2006; Kuh et al., 2009] and are
predictors of increased morbidity [Cooper et al., 2011; Guralnik
et al., 1995; Ortega et al., 2008] and mortality rate [Cooper et al.,
2010]. Twin studies have shown that measures of physical
capability are partly heritable [Arden and Spector, 1997; Carmelli
et al., 2000; Tiainen et al., 2004]; for example, in older females the
genetic component has been shown to explain 14% of grip
strength variability [Tiainen et al., 2004]. Therefore, it has been
hypothesized that the ACTN3 R577X genotype may be associated
with measures of physical capability. In the general population,
one investigation suggested associations between R577X and
decline in walk times in older men and persistent lower extremity
limitation in older women [Delmonico et al., 2008]. Another
study [Moran et al., 2007] observed that the R allele was associated
with faster sprint times in adolescent males, but not in females,
whereas another study of young adults showed no effect [Santiago
et al., 2009]. Sex differences have also been reported regarding
associations with weight [Delmonico et al., 2008; Walsh et al.,
2008], body mass index (BMI) [Walsh et al., 2008], and physical
activity levels [Delmonico et al., 2008].
We conducted a systematic review and meta-analysis of the
reports on the relationship between the ACTN3 R577X genotype
and athletic status. We also examined associations between
ACTN3 R577X and physical capability phenotypes in seven UK
cohorts of middle-aged and older adults as part of the HALCyon
(Healthy Aging across the Life Course; www.halcyon.ac.uk)
collaborative research program, one cohort with measures at age
11 years [Golding et al., 2001], and one previously reported cross-
sectional study of adolescents [Moran et al., 2007]. We also
investigated anthropometric traits, which have been shown to be
associated with physical capability [Kuh et al., 2005b; Samson
et al., 2000]. To our knowledge, this is the first report of a meta-
analysis of the ACTN3 R577X genotype and athletic status and by
far the largest investigation into its association with physical
capability in the general population.
Materials and Methods
Literature Search on Athletic Status
A search of electronic databases was conducted to identify all
publications on ACTN3 and athletic status up to November 29,
2010. The search terms ‘‘ACTN3’’ and ‘‘actinin-3’’ were used, with
no restrictions to date or language, in Medline and Web of Science
producing 298 hits, of which 187 were duplicates. Of the 111 unique
publications, 21 studies presented data on athletes and nonathletes,
although two were from one group of authors reporting on the
interactions between ACTN3 R577X and other genotypes, having
previously reported on the ACTN3 R577X genotype alone, and six
were from one group of authors who appeared to repeat data on the
groups of controls and endurance athletes; therefore, the publication
reporting on both athletic groups and using the largest numbers is
cited here. From the remaining 14 publications, the numbers of RR,
RX, and XX individuals in the controls and athletic groups by
ancestral group were extracted or estimated from the given
percentages from 13 publications. Where available in the publica-
tion, this was also done by sex. Attempts were not successful to trace
the contact details of the authors of the one study [Saunders et al.,
2007] for which genotype frequencies were not given in the article.
Additional details extracted from the articles that were not included
in the meta-analysis but may be informative about characteristics of
the study participants include the sports or events of the athletic
groups and the source of controls. The reporting of the Hardy-
Weinberg equilibrium (HWE) test was checked in all articles,
although no exclusions were made if departure was reported in a
control group. A flow diagram of the identification of the studies is
presented in Supp. Figure S1.
Physical Capability Studies
The Avon Longitudinal Study of Parents and Children
(ALSPAC) comprises 14,541 pregnancies with estimated due dates
between April 1, 1991 and December 31, 1992, in Avon, England.
We used measurements and tests taken at 11 years (between 2003
and 2005), when all children were invited to a Focus Clinic
Session. Blood samples from the children have been collected since
birth. Ethical approval for the study was obtained from the
ALSPAC Law and Ethics Committee and Local Research Ethics
Committees. Further details of the study are available [Golding
et al., 2001].
Eureka is a cross-sectional study of 1,198 healthy 11- to 18-year-
olds recruited from 10 rural and urban schools around Trikala,
Greece. Measures of body composition, strength/power and
endurance phenotypes were taken and DNA was extracted from
buccal cell samples. Details of the study have been previously
described [Moran et al., 2006, 2007].
The Medical Research Council National Survey of Health and
Development (NSHD) comprises participants sampled from all
births in a week in March 1946 and followed up since. In 1999, at
age 53 years, men and women were visited by a research nurse and
consent for DNA extraction was given by approximately 2,900
members of the cohort. Details of the data collected and the
several phases of the study are available on the cohort’s Website
(www.nshd.mrc.ac.uk) and elsewhere [Wadsworth et al., 2006].
The English Longitudinal Study of Ageing (ELSA) comprises
men and women aged 50 years and over who originally
participated in the Health Survey for England in 1998, 1999, or
2001. Fieldwork began in 2002–2003 (Phase I) with two yearly
follow-ups and in 2004–2005 (Phase II) blood samples were
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provided by 6,231 participants. Details of the cohort have been
published [Marmot et al., 2003].
The Hertfordshire Cohort Study (HCS) consists of 2,997
participants born 1931–1939 and registered with a General
Practitioner in East, North, and West Hertfordshire who attended
a clinic in 1994–2004 (Phase I). A second assessment took place in
2004–2005 for participants in East Hertfordshire (Phase II).
Further details of study design, data collected, and summaries of
participant characteristics have been published [Syddall, 2005].
The Hertfordshire Ageing Study (HAS) comprises men and
women traced in 1994–1995, the first follow-up (Phase I), of
singleton births from 1920–1930 in North Hertfordshire. A total of
717 participants attended a clinic during which DNA was extracted.
A second follow-up took place in 2003–2005 (Phase II). Details of
the recruitment, data collected, and summaries of participant
characteristics have been described previously [Syddall et al., 2009].
The Boyd Orr cohort is a historical cohort study based on
children surveyed in 1937–1939 in English and Scottish districts.
Participants were followed up in 1997–1998 (Phase II) and again
in 2002–2003 (Phase III), during which DNA was extracted from
728 adults. Details of the study design and the data collected have
been described on its Website (www.epi.bris.ac.uk/boydorr) and
elsewhere [Martin et al., 2005].
The Caerphilly Prospective Study (CaPS) recruited 2,512 men
aged between 45 and 59 years in 1979–1983 from the town of
Caerphilly, South Wales, and its surrounding villages. Blood
samples were collected at baseline and at each of the four follow-
ups (Phase II: 1984–1988, Phase III: 1989–1993, Phase IV:
1993–1997, and Phase V: 2002–2004.) Further details are available
on the cohort’s Website (www.epi.bris.ac.uk/caerphilly/caerphilly-
prospectivestudy.htm).
The Lothian Birth Cohort 1921 Study (LBC1921) participants
were all born in 1921 and completed an IQ assessment age 11.
In 1999–2001 (Phase I) 550 79-year-olds, living in and around
Edinburgh, attended a clinic, and in 2003–2005 (Phase II) 321
returned at 83 years old. Details of the recruitment into the study are
available on its Website (www.lothianbirthcohort.ed.ac.uk) and have
been published previously [Deary et al., 2004; Gow et al., 2008].
Genotyping and Quality Control
Genotyping for ACTN3 SNP rs1815739 (R577X) for all studies,
except LBC1921, ALSPAC and Eureka, was carried out by
KBioscience (www.kbioscience.co.uk). Genotype information in
LBC1921 and ALSPAC came from genome-wide scans performed
on the Illumina (www.illumina.com) Human610-Quadv1 Chip and
Human-Hap317K BeadChip, respectively [Houlihan et al., 2010;
Timpson et al., 2009]. In Eureka, genotypes were assessed using the
TaqMan SNP Assay C_590093_1 (Applied Biosystems, Melbourne,
Australia; www.appliedbiosystems.com.au) with around 10% of
genotypes validated using RFLP or direct sequencing. Data quality
was reviewed by assessing departure from HWE, clustering quality
(using KBioscience software SNPviewer on their data) and call rates.
Phenotypes
Categorization of athletic status in literature
Descriptions of the sports or events among the athletic groups,
as given in the publications, as well as their classification into
either sprint/power or endurance status, for the studies included
in the meta-analysis, are presented in Supp. Table S1.
Anthropometry
Measurements were conducted either at clinics, during a clinical
interview in the home, from self-report, or, in Eureka, during physical
education classes. BMI (kg/m2) was calculated as weight divided by
height squared. Waist-hip ratio (WHR) was defined as waist circum-
ference (cm) divided by hip circumference (cm) and was measured in
ALSPAC, NSHD, ELSA, HCS, HAS, Boyd Orr, and CaPS.
Physical capability and activity
The physical capability measures taken in the different studies are
listed in Table 1. Grip strength was measured using electronic or
hydraulic dynamometers, with the best measure used in the analysis
where more than one trial was conducted. Standing balance tests
were conducted in the studies, with participants’ eyes open:
flamingo [Committee of Experts on Sports Research, 1993]
(stopped at 30 sec) and side-by-side, semitandem and full tandem
[Stevens et al., 2008]. Poor standing balance was defined for this
analysis as the inability to complete 30 sec, or 5 sec of the full
tandem. The timed get up and go test [Podsiadlo and Richardson,
1991] required participants to get up from a chair, walk 3 m, turn,
walk back, turn, and sit down. Timed walks over 2.44 m (8 feet) and
6 m were carried out with the fastest time used in the analysis where
more than one trial was conducted. Natural log transformations
were used to improve the normality of timed walks and get up and
go. Timed chair rises [Csuka and McCarty, 1985] involved asking
participants to rise from a chair and sit back down 5 or 10 times;
the reciprocal of time taken in seconds 100 [Kuh et al., 2005a]
Table 1. Summary of Sex, Age, and ACTN3 R577X Minor Allele Frequencies by Cohort
Cohort Agea in years, median (range) Male, % MAF Total Physical capability measures included in present analysis
ALSPAC 11 (10–13) 51 0.44 2,967 Grip strength
Eureka 15 (11–18) 53 0.42 992 Grip strength
NSHD 53 50 0.44 2,595 Grip strength, standing balance,b timed chair rises
ELSA 65 (52–901) 46 0.44 5,435 Grip strength, standing balance,b timed walk,c timed chair risesd
HCS 66 (59–73) 53 0.43 2,831 Grip strength, standing balance,b TGUG, timed chair risesd
HAS 67 (63–73) 61 0.42 508 Grip strength, TGUG, timed chair risesd
Boyd Orr 70 (64–82) 46 0.46 684 Standing balance,b TGUG
CaPS 73 (65–83) 100 0.42 1,309 Standing balance,b TGUG
LBC1921 79 (77–80) 41 0.45 514 Grip strength, timed walkc
Total 60 (10–901) 53 0.43 17,835
aAge at phase from which the majority of variables are taken.
bFlamingo in NSHD, HCS, HAS, Boyd Orr, and CaPS; side-by-side, semitandem, and full tandem in ELSA.
c2.44 m (8 feet) in ELSA, 6 m in LBC1921.
dFive rises in ELSA, HCS, and HAS, 10 rises in NSHD. Genotype frequencies by sex presented in Suppl. Table S2. Minor allele: X. TGUG, timed get up and go.
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was used in the analysis. Levels of physical activity were derived
from self reports levels using questionnaires.
Statistical Methods
Statistical analysis was performed in Stata 11.1 (StataCorp LP).
A two-tailed significance level of Po0.05 was used. Reporting of
the meta-analyses met the appropriate items of a recommended
checklist [Stroup et al., 2000].
Studies of athletic status
Fixed and random-effects meta-analyses [Egger et al., 1997a]
using inverse-variance weighting were used to combine results from
the studies on athletic status, using odds ratios, for the following
comparisons: sprint/power versus controls, endurance versus
controls, and sprint/power versus endurance. Due to a number of
studies reporting no XX individuals among sprint/power athletes
[Massidda et al., 2009; Roth et al., 2008; Yang et al., 2003, 2007] or
among their respective controls [Yang et al., 2007], a dominant
model for the X allele (RR vs. RX1XX) was used in the analysis
for sprint/power versus controls or endurance, whereas both a
dominant and recessive (RR1RX vs. XX) model were used in
endurance versus controls. Data were stratified by ancestral group
and, where data were reported separately in males or females, by
sex. To investigate publication bias, or more broadly, ‘‘small study
effects,’’ funnel plots, and the Egger test were used [Egger et al.,
1997a,b]. Heterogeneity was investigated, with the I2 measure used
for its quantification [Higgins et al., 2003].
Studies of physical capability
Where information on ancestry was collected, non-European
participants were excluded from the analyses in order to avoid
confounding from population stratification [Cordell and Clayton,
2005]. Within studies, linear and logistic regression analyses were
conducted on the continuous and dichotomous traits within
the cohorts, respectively. Additive models were used with
genotypes coded as 0, 1, and 2 for the number of X alleles.
Likelihood ratio tests were used to compare the fit of the additive
models compared with the full genotype model. For continuous
traits, the normality of the standardized residuals was inspected
with distributional diagnostic plots. Cook’s distances [Cook,
2000] were plotted against fitted values, using a cutoff of four
divided by sample size, to identify influential outliers in the
continuous phenotypes. For the harmonization of continuous
Figure 1. Associations between ACTN3 R577X genotype (RR vs. RX1XX) and sprint/power athletic status from the literature. Arrow
indicates the confidence interval extends beyond the plot axis. Stratified by ancestral group. Effects are given as odds ratios (OR) and 95%
confidence intervals (CI). Points and the horizontal lines represent the study effect sizes and their 95% CIs. Sizes of the squares represent the
weights of the studies. Diamonds represent the summary effects and their 95% CIs. I–V: inverse-variance, fixed effect model. D1L: DerSimonian
& Laird, random effects model.
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traits that were used to obtain pooled estimates of the genotypic
effects, z-score units were calculated in each study by subtracting
the study mean and dividing by its standard deviation, using the
data on the individuals included in the present analysis only. The
overall mean for z-scores is 0 and standard deviation 1. Beta
coefficients calculated on z-score units can be reverted to the
original scale by multiplying by an appropriate standard deviation.
Two-step [Riley et al., 2010] meta-analyses were performed to
obtain pooled genotypic effects, with the P-values from the
random-effects model presented in the tables. The I2 measure was
used to quantify heterogeneity. Due to the different genotypic
effects reported (Introduction), z-scores were calculated and
analyses were performed separately in males and females. In
addition, analyses were also stratified by physical activity, an
indicator shown to modify genotypic effects on anthropometric
measures [Li et al., 2010]. Within-study investigations were also
made into follow-up measures of grip strength adjusting for the
measure in an earlier phase in HCS, HAS, and LBC1921, due to its
collection in more than one phase in those studies. Quanto
[Gauderman and Morrison, 2006] was used for power calculations
using the overall MAF of 0.43.
Results
Studies of Athletic Status
All studies described the types of sports or events performed in
the athletic groups. All but one study stated that the HWE test was
carried out and there was no evidence of departure among any of
the control groups.
There were 10 studies comparing sprint/power athletes to
controls, eight of which contained data on people described as
Caucasians. The MAF in controls in seven of the eight studies in
Europeans were between 0.39 and 0.49 (Supp. Table S1). The
forest plot of the meta-analysis in Figure 1 shows that overall in
Europeans there is evidence that the RR genotype is more
common among sprint/power athletes than controls. However,
there was significant heterogeneity (I25 80%, Po0.001), with one
study reporting higher frequencies of RR among the controls,
although its result was consistent with chance. The Egger test
showed that there was little evidence to suggest the presence of
‘‘small study effects’’ for the eight studies on Europeans (P5 0.2;
funnel plot presented in Supp. Fig. S2). Similar results were found
after the removal of the initial study, the removal of the study in
Europeans reporting a lower MAF of 0.32 (data not shown), and
stratifying by sex (Supp. Fig. S3). There was no evidence for an
association among non-Europeans.
There were nine studies included in the meta-analysis
comparing endurance athletes with controls. Overall, there was
no evidence that the X allele is more common among endurance
athletes under the recessive model (Fig. 2), although there was
significant heterogeneity in Europeans (I25 80%, Po0.001), with
one study finding the XX genotype more common among
controls. Similarly, there was no evidence under the dominant
model (Supp. Fig. S4) or when considering males and females
separately (Supp. Figs. S5 and S6).
Figure 2. Associations between ACTN3 R577X genotype (XX vs. RX1RR) and endurance athletic status from the literature. Arrow indicates the
confidence interval extends beyond the plot axis. Stratified by ancestral group. Effects are given as odds ratios (OR) and 95% confidence intervals (CI).
Points and the horizontal lines represent the study effect sizes and their 95% CIs. Sizes of the squares represent the weights of the studies. Diamonds
represent the summary effects and their 95% CIs. I–V: inverse-variance, fixed effect model. D1L: DerSimonian & Laird, random effects model.
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Five studies included both sprint/power and endurance athletes.
There was evidence that the RR genotype was more common
among sprint/power athletes compared with endurance athletes
(Supp. Fig. S7).
Studies of Physical Capability
Relevant genotypic and phenotypic information were available
for a total of 17,835 individuals aged between 10 and 901 years
old (Table 1 and Supp. Table S2). The quality of the genotyping
was good with call rates exceeding 94% and the HWE condition
being met (P40.07). In ELSA, the study with the widest age
range, the genotype frequencies were similar in those under and
over 70 years in both the males and females (data not shown).
Supp. Table S3 shows there was no evidence for an association
between R577X and height, weight, BMI, or WHR in either males
or females (pooled P40.1). As there was no evidence for
associations with BMI, it was not included in the models for
physical capability. No associations were found between level of
physical activity and R577X (Supp. Table S4) in either sex.
Figure 3 and Supp. Table S5 show a trend toward an association
between the R allele and better grip strength in males (P5 0.09)
and although this was not seen in females, there was no evidence
for a sex difference in this association (P5 0.2 for heterogeneity
between males and females). The results were similar after
adjusting for height. In addition, there was no evidence of
associations with grip strength in the follow-up phases adjusting
for its measure at a previous phase in HCS, HAS, or LBC1921
(data not shown). There was no evidence for an association with
other measures of physical capability (Figs. 4–6, Supp. Table S5).
After stratifying by physical activity in the analyses of
anthropometric and physical capability traits, results did not
differ substantially, except for chair rises in females, where a
significant association in ELSA was only seen in the physically
active group (P-value for interaction in ELSA5 0.008; data not
shown).
The forest plots, ordered by median study age, showed no
consistent trend in effect sizes for the studies.
In only a small number of tests did the full genotype model
represent a significantly better fit than the per allele model:
physical activity and timed walk in LBC1921 females and standing
balance in NSHD males.
Discussion
We conducted a meta-analysis of results from the published
literature on the associations between ACTN3 R577X and athletic
status, as well as investigated associations between this poly-
morphism and physical capability and anthropometry phenotypes
in 17,835 preadolescent, adolescent, and older individuals from
nine studies of the general population. We found evidence that
among Europeans the RR genotype is more common among
Figure 3. Associations between ACTN3 R577X genotype and grip strength. Studies ordered by overall median age. Effects are given as per X
allele change in grip strength (z-score) and 95% confidence intervals (CI). Points and the horizontal lines represent the study effect sizes and
their 95% CIs. Sizes of the squares represent the weights of the studies. Diamonds represent the summary effects and their 95% CIs. I–V:
inverse-variance, fixed effect model. D1L: DerSimonian & Laird, random effects model.
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sprint/power athletes compared with their controls, but there was
little evidence to support an association with ACTN3 R577X and
physical capability.
The initial report [Yang et al., 2003] of an overrepresentation of
the R allele in sprint/power athletes compared with controls also
hypothesized that the XX genotype may be advantageous to
endurance athleticism. Since then, a number of findings have
replicated the association with sprint/power performance
[Druzhevskaya et al., 2008; Eynon et al., 2009b; Moran et al.,
2007; Niemi and Majamaa, 2005; Papadimitriou et al., 2008; Roth
et al., 2008; Santiago et al., 2008], but there has been little evidence
to support the role of the XX genotype in improving endurance
athleticism. One study in Europeans [Eynon et al., 2009b] found
an overrepresentation of the XX genotype in endurance athletes,
but conversely, another investigation found a lower XX genotype
frequency among endurance athletes [Ahmetov et al., 2008]. The
meta-analysis reported here shows that, although there was
significant heterogeneity, based on the current literature there is
evidence to support the hypothesis that the RR genotype is more
common among sprint/power athletes compared with controls in
both male and female Europeans. Although there were too few
studies to formally investigate the heterogeneity with meta-
regression (Cochrane Handbook for Systematic Reviews of
Interventions, Version 5.0.2), there appeared to be no relationship
between the study effect sizes and the proportion of athletes at
international level. We found no evidence for ‘‘small study effects’’
among the studies in Europeans, although the test is likely to be
underpowered here given the small number of published studies
[Sterne et al., 2000]. Although sprint/power athletes differed from
endurance athletes, we found no evidence that endurance athletes
differed from controls with respect to the R577X genotype;
therefore, the findings can be summarized as a sprint/power
versus nonsprint/nonpower athlete association.
Type IIb muscle fibers are fast twitch white fibers fueled by
glycolysis and glycogen, which contrast with type IIa fast twitch
fibers and type I slow twitch fibers, both of which are red
(myoglobin rich) and generate ATP by oxidative phosphorylation.
Type IIb fibers fatigue easily as their energy supply cannot be
sustained by glycolysis and glycogen. An earlier report [Vincent
et al., 2007] indicated a difference of type IIb muscle fiber content,
9 versus 14% of total fibers in vastus lateralis in XX versus RR
(P5 0.04), and also showed a major difference, as expected, of
ACTN3 content according to genotype. A larger study [Norman
et al., 2009] did not find a fiber content difference, or effects on
power output, fatigability or force–velocity relationship, but did
find that repeated exercise bouts may increase dynamic torque
generation in RR genotype by 4–10%, dependent on angular
velocity. ACTN2 upregulation may partially compensate ACTN3
activity differences [Norman et al., 2009]. In a mouse ACTN3
knockout, skeletal muscle showed increased glycogen by 5–30%
according to which muscle, lower glycogen phosphorylase, which is
rate limiting in glycogen usage, and altered calcium signaling
[Quinlan et al., 2010]. Thus, although the effects at the gene
expression level are qualitative, at the structural and metabolic levels
they are more subtle, although apparently translating also into an
overrepresentation of RR genotype in sprint/power athletes (Fig. 1).
Figure 4. Associations between ACTN3 R577X genotype and timed get up and go/walk. Studies ordered by overall median age. Effects are
given as per X allele change in timed get up and go or walk (z-score) and 95% confidence intervals (CI). Points and the horizontal lines represent
the study effect sizes and their 95% CIs. Sizes of the squares represent the weights of the studies. Diamonds represent the summary effects and
their 95% CIs. I–V: inverse-variance, fixed effect model. D1L: DerSimonian & Laird, random effects model.
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From our population-based studies we found no evidence for
an association between R577X and the anthropometric or physical
capability measures, even before correcting for multiple testing.
There was, however, a trend toward 577R male carriers having
better grip strength, a power-orientated phenotype, although this
was consistent with chance (P5 0.09). The lack of association
found with our physical capability traits suggests that although the
ACTN3 R577X SNP may be associated with sprint/power athletic
status, it contributes little or not at all to the interindividual
variability in the capacity to undertake the physical tasks of daily
living in the general population at any stage of life.
From the previous smaller studies carried out in the general
population, the X allele has been associated with lower knee
extensor peak torque in women (although not men) [Walsh et al.,
2008] and men [Vincent et al., 2007], lower midthigh cross-
sectional area in women [Zempo et al., 2010], lower elbow
maximal voluntary contraction strength in women (not men)
[Clarkson et al., 2005], greater decline in 5-year 400-m walk
speeds in men (not women) [Delmonico et al., 2008], and
increased risk in women of persistent lower extremity limitation
(not men) [Delmonico et al., 2008] and falls [Judson et al., 2010].
In our study of physical capability, sample size calculations for the
quantitative traits estimated that around 3,300 individuals would
be required to detect a beta coefficient of 0.07 z-score units, or
around 6,400 individuals for 0.05 z-score units, with 80% power at
the 5% significance level. In grip strength, for example, 0.05
z-score units would correspond to a difference between the RR
and XX groups of around 0.8 kg in men and 0.6 kg in women,
assuming standard deviations of 8 and 6, respectively. Such effects
on physical capability in older age would be of interest and are
also potentially relevant to the loss of muscle mass with age due to
muscle atrophy. They may also be relevant to the mechanisms of
response to therapeutic strategies such as functional electrical
stimulation used in rehabilitation [Squecco et al., 2009] and to
strategies that could, for example, alter muscle glycogen content.
We had sufficient power to detect differences as small as 0.07
z-score units for all our traits in males and females; therefore,
if there are any associations between ACTN3 R577X and these
physical capability traits in adolescents or older adults, they are
very modest. Indeed, one other study of older adults found no
associations between R577X and 6-m walk times, grip strength,
and five chair rise times [Delmonico et al., 2008]. However, it
remains possible that ACTN3 genotype is of consequence when
considered in conjunction with other genetic variants, and it is
likely to be only one of many polymorphisms that compose a
genetic profile that is beneficial to sprint/power performance
[Ruiz et al., 2010]. Also, much work remains to be done on the
mode of action of ACTN3 genotype on sprint/power performance.
Limitations
Although our aim was to include all publications investigating
differences in genotype frequencies in athletes and nonathletes, we
were unable to get frequencies from one large study [Saunders
et al., 2007] on Ironman triathletes, although the lack of
association found in that study is consistent with the results from
our meta-analysis on endurance athletic status using all other
studies. The absence of precise athletic phenotypes is clear in this
Figure 5. Associations between ACNT3 R577X genotype and timed chair rises. Studies ordered by overall median age. Effects are given as
per X allele change in timed chair rises (z-score) and 95% confidence intervals (CI). Points and the horizontal lines represent the study effect
sizes and their 95% CIs. Sizes of the squares represent the weights of the studies. Diamonds represent the summary effects and their 95% CIs.
I–V: inverse-variance, fixed effect model. D1L: DerSimonian & Laird, random effects model.
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meta-analysis, as the composition of the endurance and sprint/
power athletic groups is diverse, with different sports and levels of
achievement among the athletes. The majority of the studies
sampled controls from the general population and although the
current low number of studies limits formal investigation into the
effects of using sedentary sex-matched controls instead, it is
suggested that future investigations should take information such
as the physical activity levels measured objectively from the use of
accelerometers, for example, of their controls into consideration
either with appropriate subgroup analysis or in the selection of the
controls. In populations of primarily African ancestry, there was
no apparent effect of R577X genotype on sprint/power athletic
status. However, statistical power may be low due to the small
number of studies and the lower X allele frequency in African
populations [MacArthur et al., 2007; Yang et al., 2007]. It is also
possible that environmental factors or other genetic factors might
modify the R577X effects. Investigations in other non-European
populations are also warranted.
In our studies of physical capability the levels of physical
activity were derived from self reports. Although we found no
association between R577X and physical activity, as expected given
both athletic groups would be considered highly physically active,
the lack of precise objective measures may have limited our ability
to identify subtle interaction effects between physical activity levels
and R577X on physical capability. The lack of evidence found for
associations with physical capability traits from our nine studies
do not rule out an association of small magnitude between R577X
and the other phenotypes reported in smaller population-based
studies. Rather, studies with greater statistical power are required
to satisfactorily investigate those traits as well as resolve the
observed sex differences found for them.
Conclusion
Our meta-analysis of results from the published literature
provides evidence for an overrepresentation of the ACTN3 R577X
RR genotype in sprint/power athletes in Europeans, although it
does not support the hypothesis that the X allele is advantageous
to endurance athletic status. We found little evidence of
associations between R577X and physical capability traits in
adolescence or later in the life course.
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